Related Experiment Videos
Scleroderma-like reaction induced by uracil-tegafur (UFT), a second-generation anticancer agent
1Department of Dermatology, First Department of Internal Medicine, Osaka City University Medical School, Japan.
Journal of the American Academy of Dermatology
|February 25, 2000
Summary
UFT, an anticancer drug, can cause a rare scleroderma-like reaction with long-term use. This case study is the first to document this specific side effect of uracil and tegafur (UFT).
Area of Science:
- Oncology
- Dermatology
Background:
- UFT (uracil and tegafur) is a second-generation anticancer agent used globally.
- It has been extensively studied for various cancers, including colorectal and pancreatic cancer, often in combination with leukovorin.
Observation:
- A patient developed a scleroderma-like reaction during long-term UFT administration.
- This reaction presented as skin hardening and other characteristic features of scleroderma.
Findings:
- This case represents the first documented instance of a scleroderma-like reaction specifically induced by UFT.
- The reaction suggests a potential, albeit rare, adverse effect of this chemotherapy agent.
Implications:
- Highlights the importance of monitoring for dermatological side effects in patients on long-term UFT therapy.
- Suggests a need for further investigation into the mechanisms of UFT-induced cutaneous toxicity.
- Informs clinical practice regarding potential risks associated with uracil and tegafur treatment.